Abstract
In vitro intrinsic metabolic clearance (CLint) is used routinely for compound selection in drug discovery; however, in vitro CLint often underpredicts in vivo clearance (CL). Forty-one proprietary compounds and 16 marketed drugs were selected to determine whether permeability and efflux status could influence the predictability of CL from in vitro CLint obtained from liver microsomal and hepatocyte incubations. For many of the proprietary compounds examined, rat CL was significantly underpredicted using the well stirred model incorporating both fraction of unbound drug in blood and fraction of unbound drug in the microsomal or hepatocyte incubation. Further analysis revealed that the accuracy of the prediction was differentiated by permeability and P-glycoprotein- (P-gp) and mouse breast cancer resistance protein (mBcrp)-mediated efflux. For proprietary compounds with passive permeability greater than 5 × 10−6 cm/s and efflux ratios less than 5 in both P-gp- and mBcrp-expressing cells, CLint provided reasonable prediction. The average -fold error (AFE) was 1.8 for rat liver microsomes (RLMs) and 2.3 for rat hepatocytes. In contrast, CL was dramatically underpredicted for compounds with passive permeability less than 5 × 10−6 cm/s; AFEs of 54.4 and 29.2 were observed for RLM and rat hepatocytes, respectively. In vivo CL was also underpredicted for compounds that were good efflux substrates (permeability >5 × 10−6 cm/s). The AFEs were 7.4 and 8.1 for RLM and rat hepatocytes, respectively. A similar relationship between permeability, efflux status, and human CL prediction reported in the literature was observed for 16 marketed drugs. These data show that permeability and efflux status are determinants for the predictability of CL from in vitro metabolic CLint.
Footnotes
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.109.029066.
-
↵ The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
-
- CLint
- in vitro intrinsic metabolic clearance
- CL
- clearance
- fub
- fraction of unbound drug in blood
- fuinc
- fraction of unbound drug in the microsomal or hepatocyte incubation
- fup
- fraction of unbound drug in plasma
- P-gp
- P-glycoprotein
- Bcrp
- breast cancer resistance protein
- RLM
- rat liver microsome
- DMEM
- Dulbecco's modified Eagle's medium
- HBSS
- Hanks' balanced salt solution
- FBS
- fetal bovine serum
- MDR1-LLC-PK1
- porcine renal epithelial cells transfected with human MDR1 gene
- mBcrp-MDCK cells
- Madin-Darby canine kidney cells transfected with mouse ABCG2 gene
- MDCK
- Madin-Darby canine kidney cells transfected with control vector
- LC/MS/MS
- liquid chromatography tandem mass spectrometry system
- BSA
- bovine serum albumin
- Papp
- apparent permeability value
- GF120918
- N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide
- AUC0-inf
- area under the concentration versus time curve from time 0 to infinity
- AFE
- average -fold error
- PSA
- polar surface area.
- Received June 18, 2009.
- Accepted October 27, 2009.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|